Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C

Stella De Nicola1, Paola Dongiovanni2, ALESSIO AGHEMO1, Cristina Cheroni3, Roberta D’Ambrosio1,4, Michele Pedrazzini5, Francesco Marabita3, Lorena Donnici3, Marco Maggioni5, Silvia Fargion2,4, Massimo Colombo1,4, Raffaele De Francesco3,*, Luca Valenti2,4, LUCA VALENTI2,4

1 Department of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Milano, Italy, 2 Department of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Milano, Italy, 3 Virology Program, INGM - Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Milano, Italy, 4 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy, 5 Department of Pathology, Fondazione IRCCS Ca’ Granda Ospedale Policlinico Milano, Milano, Italy

Abstract

Background and Aims: The PNPLA3 I148M sequence variant favors hepatic lipid accumulation and confers susceptibility to hepatic fibrosis and hepatocellular carcinoma. The aim of this study was to estimate the effect size of homozygosity for the PNPLA3 I148M variant (148M/M) on the fibrosis progression rate (FPR) and the interaction with age at infection in chronic hepatitis C (CHC).

Methods: FPR was estimated in a prospective cohort of 247 CHC patients without alcohol intake and diabetes, with careful estimation of age at infection and determination of fibrosis stage by Ishak score.

Results: Older age at infection was the strongest determinant of FPR (p<0.0001). PNPLA3 148M/M was associated with faster FPR in individuals infected at older age (above the median, 21 years; −0.64±0.2, n=8 vs. −0.95±0.3, n=166 log10 FPR respectively; p=0.001; confirmed for lower age thresholds, p<0.05), but not in those infected at younger age (p=ns). The negative impact of PNPLA3 148M/M on fibrosis progression was more marked in subjects at risk of altered hepatic lipid metabolism (those with grade 2–3 steatosis, genotype 3, and overweight; p<0.05). At multivariate analysis, PNPLA3 148M/M was associated with FPR (incremental effect 0.08±0.03 log10 fibrosis unit per year; p=0.022), independently of several confounders, and there was a significant interaction between 148M/M and older age at infection (p=0.025). The association between 148M/M and FPR remained significant even after adjustment for steatosis severity (p=0.032).

Conclusions: We observed an interaction between homozygosity for the PNPLA3 I148M variant and age at infection in determining fibrosis progression in CHC patients.

Introduction

Hepatitis C virus (HCV) infection affects roughly 130–170 million people worldwide. Individuals with chronic HCV-related hepatitis (CHC) are at high risk of liver fibrosis, an in about 20% of cases CHC progresses to cirrhosis. Therefore, HCV is a leading cause of end-stage liver disease and hepatocellular carcinoma [1]. Older age at infection, genotype 3, coexistent liver diseases, male gender, alcohol abuse, obesity and diabetes, and steatosis are risk factors for disease evolution [2–3].

However, even after taking into account all known viral, host related, and environmental factors, the rate of progression to advanced fibrosis is highly variable among individuals, thereby suggesting a role for inherited variants. Indeed, single-nucleotide polymorphisms at different genetic loci have been associated with fibrosis progression in candidate gene studies [6,7].
The rs738409 C>G polymorphism of *Patatin-like phospholipase domain-containing 3* (*PNPLA3*), encoding for the I148M protein sequence variant, is the major common genetic determinant of hepatic fat content. The I148M variant influences the metabolism of triglycerides, lipid droplets remodeling, and lipoprotein secretion in hepatocytes [8–13]. *PNPLA3* I148M is the major risk factor for both alcoholic and nonalcoholic steatohepatitis, showing an age-modulated effect on liver damage susceptibility and fibrogenesis [14–19]. Recently, it has been reported that homozygosity for the 148M risk allele (henceforth *PNPLA3* 148M/M) also influences the risk of advanced fibrosis and hepatocellular carcinoma in CHC [20–25]. However, scant data are derived from prospective studies [23,25], and the interaction with age at infection has not been evaluated so far.

Therefore, the aim of this study was to estimate the effect size of *PNPLA3* 148M/M on fibrosis progression rate (FPR) and the interaction with age at infection in a unique validated cohort of 247 CHC subjects without significant alcohol intake and diabetes, characterized by a careful estimation of age at infection and with histological determination of liver damage [3].

**Materials and Methods**

**Patients**

We analyzed a previous published cohort of 247 CHC patients followed-up at the Migliavacca Liver Disease Center at the Fondazione IRCCS Ca’ Granda Polyclinico of Milan [3]. Briefly, inclusion criteria comprised a precise estimate of the date of infection based on the date of the first reported risk factor, a diagnostic liver biopsy before any antiviral therapy performed at least 4 years after the date of infection, and no history of past or current alcohol abuse. Patients with viral co-infections or other liver diseases were excluded, as well as patients with either type 1 or type 2 diabetes. Disease duration was calculated considering the time elapsed from the date of infection to the time of liver biopsy. The study protocol conformed to the Declaration of Helsinki and was approved by the Institutional Review Board of the Fondazione IRCCS Ca’ Granda. Each patient signed a written informed consent.

The baseline features of the study cohort stratified by *PNPLA3* 148M/M status are presented in table 1. The study database has been uploaded as supplementary material (Data S1).

**Histological evaluation**

Liver histology was evaluated by a single expert pathologist. Mean biopsy length was 26.3 mm. The severity of hepatic inflammation was evaluated by the Ishak score [26], entailing a maximum of 18 points for grading (G) and 6 points for liver staging (S). All specimens were also evaluated for steatosis severity (grade 0: absent or <5%; grade 1: 5–33%; grade 2: 34–66%; grade 3: >66% of hepatocytes affected) [27]. Steatosis assessment is missing for 14 patients due to the inability to recollect the original histological slides re-evaluated for fibrosis stage. To analyze the effect of steatosis severity in the whole study cohort, additional analyses were conducted estimating the severity of steatosis in these 14 subjects by ultrasonography [28].

**Genetic analysis**

Genomic DNA was obtained from peripheral whole blood as previously described [3]. The *PNPLA3* rs738409 C>G single nucleotide polymorphism, encoding for the I148M protein sequence variant, was genotyped by a 5’ nucleic Taqman assay (LifeTechnologies, Carlsbad, CA, USA) at the Metabolic Liver Diseases lab at the Fondazione Ca’ Granda IRCCS. Success rate was 100% and perfect concordance between duplicates and internal controls was observed.

**Statistical analysis**

For descriptive statistics, variables were shown as mean ± SD and frequencies, and compared by Student’s t-test or chi-square test according to data distribution. P values were considered significant when <0.05 (two-tailed). FPR was calculated by taking the ratio between the staging value of Ishak score and the disease duration (years), and it was treated as a continuous variable. Mean disease duration was 25 ± 10 years. Log10 transformation of FPR was employed to obtain linearity. FPR estimation assumes that no significant liver fibrosis was present at the time of infection, and that liver fibrosis progression is constant during time [2]. A first generalized linear model was formulated and fitted to the data, specifying the presence of *PNPLA3* 148M/M at risk genotype [21–23], and the covariates as explanatory variables. We considered as covaried the independent predictors of FPR in a previously reported analysis of the same cohort [3]: age at infection (encoded as > or ≤ the median value, 21 years), gender, and HCV genotype. The product term age at infection × *PNPLA3* 148M/M was fitted into the model to test the interaction between *PNPLA3* genotype and age at infection on FPR. To account for other potential confounders, a second model was tested, with further adjustment for the route of HCV transmission (intra-venous drug use: IVDU or other), body-mass (BMI < or ≥ 25 Kg/m²), and age at liver biopsy. Finally, to check whether the relationship between *PNPLA3* genotype and FPR was independent of steatosis, a final model further adjusted for the histological severity of steatosis (grade 2–3 vs. 0–1) was evaluated. Models were checked through the regression diagnostic plots to verify normality, linearity of the data, and constant variance. The effect of the explanatory variables was considered significant if p < 0.05 (two-tailed). Analyses were performed by the SPSS 21.0 (IBM, Burbank, NY, USA) statistical analysis software.

**Results**

**Study cohort**

Detailed characterization of the study cohort has previously been reported [3]. Briefly, 52% of patients were males, the majority infected by genotype 1 (52%), during blood transfusion (75%). Median age at infection was 21 years and disease duration 25 years. At the time of histological evaluation, 16% of patients had cirrhosis, whereas severe steatosis (grade 2–3) was observed in 20% of cases. The frequency distribution of the *PNPLA3* I148M variant did not violate Hardy-Weinberg equilibrium (p>0.8), and was in line with that expected unselected subjects: 120 patients were *PNPLA3* 148I/I (48%), 106 148I/M (43%), and 21 had the unfavorable 148M/M genotype (9%).

Clinical features of patients stratified by *PNPLA3* 148M/M status are presented in table 1. Demographic and anthropometric features, viral genotype distribution, age and route of infection, and duration of follow-up did not differ according to *PNPLA3* 148M/M status (p = ns). There was no statistically significant difference in the prevalence of grade 2–3 steatosis according to *PNPLA3* 148M/M status (p = ns), although a nonsignificant trend was observed in the whole cohort including subjects with ultrasonographic estimation of steatosis severity (7/21, 33% vs. 44/226, 19% in 148M/M vs. individuals carrying other *PNPLA3* genotypes, p = 0.15).
Effect of age at infection and PNPLA3 I148M on fibrosis progression

Older age at infection was strongly associated with FPR (log_{10} FPR −1.1 ± 0.3 vs. −0.9 ± 0.3 in subjects younger or older than 21 years, median value, respectively; p < 0.0001). The FPR stratified by age at infection (> or ≤ median value, 21 years) and PNPLA3 I148M and is presented in figure 1 and in table 2. PNPLA3 I148M was associated with faster FPR in older (p = 0.001), but not in younger patients (p = ns). The positive association between PNPLA3 I148M and FPR in older patients was confirmed in sensitivity analyses using different age cut-offs (table 2): 15 years, the 25th centile (p = 0.038), 18 years (p = 0.045), and 27 years, the 75th centile (p = 0.01).

Steatogenic factors, PNPLA3 I148M, and fibrosis progression

Moderate-severe steatosis was associated with faster FPR (log_{10} FPR −1.1 ± 0.3 vs. −0.9 ± 0.3 in subjects with steatosis grade 0–1, n = 186 vs. grade 2–3, n = 47, respectively; p = 0.016). The association between steatosis grade 2–3 and FPR was confirmed in the whole cohort including subjects with ultrasonographic estimation of steatosis severity (log_{10} FPR −1.1 ± 0.3 vs. −0.9 ± 0.3 in subjects with steatosis grade 0–1, n = 196 vs. grade 2–3, n = 51, respectively; p = 0.012). Since PNPLA3 I148M interferes with hepatocellular lipid metabolism, we next evaluated whether the effect of PNPLA3 I148M on FPR was influenced by steatosis severity and risk factors for derangement of hepatic lipid metabolism. Results are shown in table 3. The association of PNPLA3 I148M with FPR was more consistent in the presence of grade 2–3 steatosis (p = 0.024), or in the presence of other steatogenic factors: namely infection with genotype 3 (p = 0.005), or overweight (p = 0.05). The association between PNPLA3 I148M and FPR was nearly significant in patients with steatosis grade 2–3 including subjects with ultrasonographic estimation of steatosis severity (p = 0.056).

Independent predictors of fibrosis progression

At the multivariate generalized linear model considering known determinants of FPR (age at infection, gender, and viral genotype: shown in model 1, table 4) PNPLA3 I148M was an independent predictor of FPR (p = 0.022). The model estimated an incremental progression of 0.08 ± 0.03 log_{10} unit of fibrosis per year conferred by I148M status. Furthermore, there was a significant interaction between PNPLA3 I148M and older age at infection in determining FPR (p = 0.025; estimate +0.07 ± 0.03). In exploratory analyses, there was no significant interaction between PNPLA3 I148M and other determinants of FPR.

To test the robustness of the association between PNPLA3 genotype and FPR, we extended the model with further adjustment for potential confounders: age at biopsy, presence of overweight, and route of infection (model 2; table 4). In this extended model, the association of PNPLA3 I148M with FPR (estimate +0.08 ± 0.03, p = 0.018), as well as the interaction with older age at infection (estimate +0.07 ± 0.03, p = 0.021) remained unaffected.

Finally, to test whether the effect of 148M/M status on fibrosis progression was independent of the histological severity of steatosis, we further adjusted the extended model for the presence of grade 2–3 steatosis (model 3; table 4). Again, PNPLA3 I148M was not (estimate +0.07 ± 0.03, p = 0.032) and the interaction with older age at infection (estimate +0.07 ± 0.03, p = 0.045) remained significantly associated with FPR independently of the steatosis severity (grade 2–3 vs. 0–1; estimate +0.04 ± 0.02, p = 0.03). In the overall series of patients including those with ultrasonographic estimation of steatosis severity (log_{10} FPR 2

Table 1. Clinical features of 247 CHC patients subdivided according to the presence of homozygosity for PNPLA3 I148M variant (148M/M).

| PNPLA3 I148M genotype | 148I/I or I/M | 148M/M | p value |
|------------------------|---------------|---------|---------|
| Age at infection years | 21.5 ± 13     | 21.7 ± 16 | 0.96    |
| Sex F                  | 109 (48)      | 9 (43)   | 0.66    |
| BMI Kg/m²              | 26.1 ± 13     | 24.9 ± 6 | 0.69    |
| Age at biopsy years    | 46.8 ± 12     | 48.4 ± 13 | 0.70    |
| HCV genotype           |               |          | 0.64    |
| G1                     | 116 (51)      | 13 (62)  |         |
| G2                     | 68 (30)       | 6 (28)   |         |
| G3                     | 32 (14)       | 2 (10)   |         |
| G4                     | 10 (5)        | 0        |         |
| Route of infection     |               |          | 0.83    |
| Transfusion            | 169 (75)      | 16 (76)  |         |
| IVDU                   | 53 (23)       | 5 (24)   |         |
| Other                  | 4 (2)         | 0        |         |
| Steatosis grade 2–3    | 42 (19)       | 5 (26)   | 0.48    |
| Disease activity (grade)| 6 (5–7)     | 6 (5–7)  | 0.78    |
| Fibrosis stage          | 2 (1–3)       | 3 (2–5)  | 0.22    |

Continuous variables are shown as mean ± SD (normally distributed) or median (interquartile range) (skewed variables); (): % values; F: female; BMI: body mass index; G: genotype; IVDU: intra-venous drug user; Other: needlestick, mother-to-child, sexual transmission.

 doi:10.1371/journal.pone.0106022.t001
Figure 1. Fibrosis progression rate (FPR) according to age at infection (> or ≤21 years, median value) and PNPLA3 148M/M status in 247 patients with chronic hepatitis C. Box plots indicate median value and interquartile ranges, whiskers the 5th and 95th centiles. p = 0.001 for faster FPR in PNPLA3 148M/M positive vs. negative patients with older age at infection (>21 years). *p < 0.0001 vs. patients with same PNPLA3 148M/M status and younger age at infection (≤21 years).

Table 2. Effect of PNPLA3 148M/M on (log10) FPR in 247 CHC patients according to different thresholds of age at infection.

| Age at infection | PNPLA3 148I/I or I/M | PNPLA3 148M/M | p value |
|------------------|----------------------|---------------|---------|
| 15 years; 25th centile (±puberty) | | | |
| Younger | −1.25 ± 0.3 (51) | −1.19 ± 0.3 (9) | ns |
| Older | −0.98 ± 0.3 (175) | −0.78 ± 0.3 (12) | 0.038 |
| 18 years; “adulthood” | | | |
| Younger | −1.25 ± 0.3 (70) | −1.19 ± 0.3 (9) | ns |
| Older | −0.99 ± 0.3 (156) | −0.78 ± 0.3 (12) | 0.045 |
| 21 years; median | | | |
| Younger | −1.14 ± 0.3 (110) | −1.16 ± 0.3 (13) | ns |
| Older | −0.95 ± 0.3 (116) | −0.64 ± 0.3 (8) | 0.001 |
| 27 years; 75th centile | | | |
| Younger | −1.10 ± 0.3 (157) | −1.11 ± 0.3 (14) | ns |
| Older | −0.90 ± 0.3 (69) | −0.67 ± 0.2 (7) | 0.01 |

(): number of subjects; ns: not significant.

doi:10.1371/journal.pone.0106022.t002
estimation of steatosis, *PNPLA3* 148M/M (estimate $+0.07 \pm 0.03$, $p = 0.033$) and the interaction with older age at infection (estimate $+0.07 \pm 0.03$, $p = 0.036$) remained significantly associated with FPR.

**Discussion**

In this paper, we showed that in a prospective cohort with careful estimation of the date of infection and absence of major confounders the *PNPLA3* 148M sequence variant influences fibrosis progression in CHC.

Homozygosity for the 148M variant, which in line with the prevalence in the Italian population [29] was detected in about one in ten subjects, was associated an average incremental progression of fibrosis stage of as much as circa 0.8 units of Ishak score per year. The link between 148M/M status and FPR was independent of known moderators of fibrogenesis in CHC [2,3,30], and remained robust even after extensive adjustment for other potential confounders.

Our study is the first to show that the effect of *PNPLA3* 148M on fibrosis progression in CHC is modulated by the age at infection. The negative impact of 148M/M on FPR in individuals infected at older age was confirmed in sensitivity analyses with lower age cut-offs, and was prominent in individuals infected in adulthood. Previous studies suggested that *PNPLA3* 148M modulates liver damage progression in an age-dependent fashion. However, despite older age at onset was associated with faster progression of liver damage in alcoholic liver disease, the effect size of 148M/M was larger in younger patients [19]. Similarly, the reported effect size of the *PNPLA3* 148M variant on liver damage in nonalcoholic fatty liver disease was larger in pediatric case series [14–16].

The reason underlying the opposite direction of modulation by age of the effect of *PNPLA3* 148M on fibrosis progression in CHC is presently unknown. It could be speculated that the pattern of activation of the immune system towards HCV is different depending on the age at infection. According to this hypothesis, HCV infection after the developmental age would lead to immune-mediated hepatic damage, exerting a permissive role on *PNPLA3* 148M-related fibrogenesis [31]. Alternatively, older age may synergize with *PNPLA3* 148M in determining hepatic steatosis, which would favor viral replication during the acute infection [32], thus setting the stage for faster disease progression.

Indeed, evidence is accumulating that *PNPLA3* 1148M synergizes with host features and environmental triggers in determining liver damage associated with altered hepatic lipid metabolism [33]. In line with these data, we found that the effect of *PNPLA3* 148M/M on fibrogenesis was more evident in subjects with grade 2–3 steatosis, and in those with other conditions favoring hepatocellular lipid accumulation, such as infection with genotype 3 and overweight.

Of note, we reported for the first time an effect of 148M/M on fibrosis progression in genotype 3 patients, even if previous studies did not detect an association between *PNPLA3* and steatosis in this subgroup [34,35]. However, since this finding was based on FPR assessment in only two 148M/M patients infected with HCV G3, it will require confirmation in future studies. Most importantly, the effect of 148M/M on fibrogenesis was independent of the histological severity of steatosis. These data are in line with results of cross-sectional studies in nonalcoholic fatty liver disease [33], and suggest that *PNPLA3* 1148M may promote fibrogenesis by directly altering hepatic stellate cells lipid metabolism and trans-activation [36].

Therefore, given the independent association of the *PNPLA3* 1148M variant with fibrosis progression and hepatocellular carcinoma risk [24], *PNPLA3* 1148M genotyping may help refining treatment prioritization to novel therapeutic regimens based on direct antiviral agents [37], and patients follow-up.

Limitations of this study include the assumption of the absence of liver fibrosis at the time of infection, which is likely given the absence of cofactors of liver damage, the young age at infection and low risk profile. Furthermore, the model tested assumes the consistency and linearity of FPR during time, and of fibrosis progression across Ishak score stages, which are approximations of a more complex reality [38]. Notwithstanding, the present results are corroborated by the fact that our approach was able to validate the association of FPR with the major risk factors for fibrosis progression in CHC [3], and by independent findings linking *PNPLA3* 148M/M with fibrogenesis in CHC [25,33].

**Conclusions**

In conclusion, homozygosity for the *PNPLA3* 1148M variant is associated with FPR in CHC. There is a significant interaction between age at infection and *PNPLA3* genotype in determining fibrosis progression, but the association between *PNPLA3* and
Table 4. Independent determinants of \((\log_{10})\) FPR at multivariate generalized linear models in 247 CHC patients.

|                     | Model 1 | Model 2 | Model 3 |
|---------------------|---------|---------|---------|
|                     | estimate | SE     | p value | estimate | SE     | p value | estimate | SE     | p value |
| Sex F               | 0.05     | 0.02    | 0.005   | 0.05     | 0.02    | 0.006   | 0.05     | 0.02    | 0.01    |
| Older age at infection | +0.21   | 0.03    | <0.0001 | +0.21    | 0.03    | <0.0001 | +0.21    | 0.04    | <0.0001 |
| HCV genotype        |         |         |         |          |         |         |          |         |         |
| G1                  | ref     | ref     | ref     |          |         |         |          |         |         |
| G2                  | −0.10   | 0.04    | 0.004   | −0.11    | 0.03    | 0.003   | −0.10    | 0.04    | 0.008   |
| G3                  | +0.13   | 0.04    | 0.002   | +0.13    | 0.04    | 0.004   | +0.11    | 0.05    | 0.02    |
| G4                  | 0.00    | 0.06    | >0.1    | 0.02     | 0.06    | >0.1    | 0.02     | 0.07    | >0.1    |
| PNPLA3 148M/M       | +0.08   | 0.03    | 0.022   | +0.08    | 0.03    | 0.018   | +0.07    | 0.03    | 0.032   |
| PNPLA3 148M/M * older age at infection | +0.07 | 0.03 | 0.025 | +0.07 | 0.03 | 0.021 | +0.07 | 0.03 | 0.045 |
| Age at biopsy       | NA      |         |         | −0.003   | 0.002   | 0.06    | −0.003   | 0.002   | 0.06    |
| BMI (>25 Kg/m²)     | NA      |         |         | −0.02    | 0.02    | >0.1    | −0.02    | 0.02    | >0.1    |
| IVDU                | NA      |         |         | −0.02    | 0.05    | >0.1    | −0.01    | 0.05    | >0.1    |
| Steatosis grade 2–3 vs. 0–1 | NA      |         |         | +0.04    | 0.02    | 0.03    |          |         |         |

NA: not addressed; F: female; BMI: body mass index; IVDU: intravenous drug use.

Model 1: minimal model considering previously identified risk factors for FPR in the present cohort [3], plus 148M/M and the interaction between 148M/M and age infection. Model 2: extended model further corrected for potential confounding factors. Model 3: extended model with additional correction for histological severity of steatosis. P values are shown for \(\leq 0.1\).

doi:10.1371/journal.pone.0106022.t004
Supporting Information

Data S1 Study database.

References

1. Maassoumy B, Wederemeyer H (2012) Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26: 401–412.

2. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825–832.

3. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, et al. (2011) Genetic variation in the Interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 53: 1127–1134.

4. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, et al. (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130: 1636–1642.

5. Adinolfi LE, Gambardella M, Andreana A, Truppoi MF, Utirli R, et al. (2003) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1350–1364.

6. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31: 828–833.

7. Trepo E, Pothoff A, Pradat P, Bakhri S, Young B, et al. (2011) Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 55: 38–44.

8. Romo S, Koulthima J, Xing C, Pertsemlidis A, Cox D, et al. (2006) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 38: 1461–1465.

9. Pirazzi C, Adels M, Burza MA, Mancina RM, Levin M, et al. (2012) Patatin-like phospholipase domain-containing 3 gene (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 57: 1257–1262.

10. Hyytala J, Gopalacharyulu P, Bian H, Yostchasten T, Levonen M, et al. (2013) Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity. Diabetes 63: 312–322.

11. Ruhanen H, Peltola JD, Holta-Vuori MD, Zhou YD, Yli-Jarvinen HP, et al. (2014) PNPLA3 mediates hepatocyte triacylglycerol remodelling. J Lipid Res.

12. He S, McPhaul C, Li JZ, Garuti R, Kinczil, et al. (2010) A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285: 6706–6715.

13. Kumari M, Schoiswohl G, Chiragru C, Paar M, Cornaciu I, et al. (2012) Adiponutrin functions as a nutritionally regulated lysophosphatidic Acid acyltransferase. Cell Metab 15: 691–702.

14. Valenti L, Al-Serri A, Dally AK, Galmozzi E, Rametta R, et al. (2010) Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51: 1209–1217.

15. Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, et al. (2010) I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 52: 1274–1280.

16. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Pediatr 158: 6706–6715.

17. Tian C, Skowklost RJ, Krenzhenbich D, Ballinger DG, Hinds DA (2009) Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42: 21–28.

18. Stickel F, Buch S, Lau K, Zu Schwabedissen HM, Berg T, et al. (2011) Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 53: 86–95.

19. Burza MA, Molinaro A, Attilia ML, Rotondo C, Attilia F, et al. (2014) PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis. Liver Int 34: 514–520.

20. Valenti L, Aghemo A, Stattmayer AF, Maggioni P, De Nicola S, et al. (2012) Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 35: 1434–1442.

21. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, et al. (2011) Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53: 791–799.

22. Muller T, Buch S, Berg T, Hampe J, Stickel F (2011) Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. J Hepatol 55: 732–733.

23. Trepo E, Pothoff A, Pradat P, Anzsonza Y, Yeroutinmout K, et al. (2011) Impact of PNPLA3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54: 60–69.

24. Trepo E, Nahon P, Bontempi G, Valenti L, Falletti E, et al. (2013) Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology.

25. Singal AG, Manjunath H, Yopp AC, Berg MS, Marrero JA, et al. (2014) The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. Am J Gastroenterol 109: 325–334.

26. Ishak K, Bapista A, Bianchi L, Callia F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696–699.

27. Kleiner DE, Bruni EM, Van Natta M, Belling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321.

28. Hamaguchi M, Kojima T, Ishi Y, Harano Y, Fujii K, et al. (2007) The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102: 2708–2715.

29. Valenti L, Rametta R, Ruscia M, Dongiovanni P, Steffani L, et al. (2012) The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol 12: 111.

30. Reggiardo MV, Fay F, Tanno M, Garcia-Camacho G, Rottato O, et al. (2012) Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects. Ann Hepatol 11: 658–666.

31. Knolle PA, Thaniree R (2014) Hepatic Immune Regulation and its Involvement in Viral Hepatitis Infection. Gastroenterology.

32. Bassendine MF, Sheridan DA, Flemmee DJ, Bridge SH, Toms GL, et al. (2011) HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol 55: 1428–1440.

33. Dongiovanni P, Donatini B, Fares R, Lombardi R, Mancina RM, et al. (2013) PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 19: 6909–6918.

34. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, et al. (2011) Viral Genotype-Specific Role of PNPLA3, PPARG, MITTP and IL28B in Hepatitis C Virus-Associated Steatosis. J Hepatol 55: 529–535.

35. Valenti L, Aghemo A, Stattmayer AF (2012) Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol 56: 1209–1210.

36. Pirazzi C, Valenti L, Moto BM, Pingitore P, Fedhali K, et al. (2014) PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet.

37. Aghemo A, De Francesco R (2013) New horizons in hepatitis C antiviral therapy: The direct-acting antivirals. Hepatology 58: 428–430.

38. Rosselli M, MacNaughtn J, Jalan R, Pinzani M (2013) Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 62: 1234–1241.

Acknowledgments

We thank all the members of the Metabolic Liver Diseases lab for helpful comments and discussion.

Author Contributions

Conceived and designed the experiments: LV RDF. Performed the experiments: PD CC RDA MP FM LD MM. Analyzed the data: LV SDN PD AA. Contributed reagents/materials/analysis tools: MC SF RDF. Contributed to the writing of the manuscript: LV SDN RDF AA CC.